In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar
Study identifies potential drug treatments for telomere diseases
Capping decades of research, a new study may offer a breakthrough in treating dyskeratosis congenita and other so-called telomere diseases, in which cells age prematurely.
Using cells donated by patients with the disease, researchers at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center identified several small molecules that appear to reverse this cellular aging process. Suneet Agarwal, the study’s senior investigator, hopes at least one of these compounds will advance toward clinical trials. Findings were published Tuesday in the journal Cell Stem Cell.
If so, it could be the first treatment for dyskeratosis congenita, or DC, that could reverse all of the disease’s varying effects on the body. The current treatment, bone marrow transplant, is high-risk, and only helps restore the blood system, whereas DC affects multiple organs.
Telomeres, telomerase, and health
The compounds identified in the study restore telomeres, protective caps on the tips of our chromosomes that regulate how our cells age. Telomeres consist of repeating sequences of DNA that get shorter each time a cell divides.
The body’s stem cells, which retain their youthful qualities, normally make an enzyme called telomerase that builds telomeres back up again. But when telomeres can’t be maintained, tissues age before their time. A spectrum of diseases can result — not just DC, but also aplastic anemia, liver cirrhosis, and pulmonary fibrosis.
The discovery of telomerase 35 years ago, earning a Nobel Prize in 2009, galvanized the scientific world. Subsequent studies suggested the enzyme could be a key to reversing aging, as well as treating cancer, in which malignant cells become “immortal” and divide indefinitely.
For years, researchers have tried to find a simple and safe way to manipulate telomerase, preserve telomeres, and create cures for telomere diseases.
“Once human telomerase was identified, there were lots of biotech startups, lots of investment,” says Agarwal, who has researched the biology of telomerase for the past decade. “But it didn’t pan out. There are no drugs on the market, and companies have come and gone.”
Finding a small molecule for telomere diseases
DC can be caused by mutations in any of multiple genes. Most of these mutations disrupt telomerase formation or function — in particular, by disrupting two molecules called TERT and TERC that join together to form telomerase. TERT is an enzyme made in stem cells, and TERC is a so-called non-coding RNA that acts as a template to create telomeres’ repeating DNA sequences. Both TERT and TERC are affected by a web of other genes that tune telomerase’s action.
One of these genes is PARN. In 2015, Agarwal and colleagues showed in Nature Genetics that PARN is important for processing and stabilizing TERC. Mutations in PARN mean less TERC, less telomerase, and prematurely shortened telomeres.
The new study, led by Harvard Medical School postdoctoral fellow Neha Nagpal, delved further, focusing on an enzyme that opposes PARN and destabilizes TERC, called PAPD5.
“We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase,” says Nagpal, first author on the paper.
Nagpal and her colleagues first conducted large-scale screening studies to identify PAPD5 inhibitors, testing more than 100,000 known chemicals. They got 480 initial “hits,” which they ultimately narrowed to a small handful.
They then tested the inhibitors in stem cells made from the Martins’ cells and those of other patients with DC. To the team’s delight, the compounds boosted TERC levels in the cells and restored telomeres to their normal length.
But the real challenge was to see if the treatment would be safe and specific, affecting only the stem cells bearing TERT. To test this, the team introduced DC-causing PARN mutations into human blood stem cells, transplanted those cells into mice, then treated the mice with oral PAPD5 inhibitors. The compounds boosted TERC and restored telomere length in the transplanted stem cells, with no adverse effect on the mice or on the ability to form different kinds of blood cells.
“This provided the hope that this could become a clinical treatment,” says Nagpal.
The road ahead
In the future, Agarwal, Nagpal, and colleagues hope to validate PAPD5 inhibition for other diseases involving faulty maintenance of telomeres — and perhaps even aging itself. They are most excited about two compounds, known as BCH001 and RG7834 that are under further development.
“We envision these to be a new class of oral medicines that target stem cells throughout the body,” Agarwal says. “We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Telomere diseases
- Telomere Stability Study Finds New Wrinkle in DNA Repair, Could Inform Anticancer Research
Discoveries about PARP1 biology generate questions that could aid in development of new PARP1-targeting strategies.
- Dogma-challenging telomere findings may offer new insights for cancer treatments
A new study led by University of Pittsburgh and UPMC Hillman Cancer Center researchers shows that an enzyme called PARP1 is involved in repair of telomeres, the lengths of DNA that protect the tips of ...
- Malaria linked with genetic changes associated with ageing: Study
Malaria report, published in 'The Lancet Microbe' journal, around 70 per cent of the global burden of the mosquito-borne disease is concentrated in 11 countries, including India and 10 African ...
- Malaria infection linked to genetic changes associated with aging, study finds
Researchers have found that adults in malaria-endemic regions of Africa have shorter telomeres, indicating accelerated aging at the genetic level ...
- Malaria may shorten leukocyte telomeres among sub-Saharan Africans
The length of telomeres in white blood cells, known as leukocytes, varies significantly among sub-Saharan African populations, researchers report. Moreover, leukocyte telomere length (LTL) is ...
Go deeper with Google Headlines on:
Telomere diseases
[google_news title=”” keyword=”telomere diseases” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
PAPD5 inhibition
- ACE Inhibitor-Related Angioedema: Can Angiotensin-Receptor Blockers Be Safely Used?
Angioedema is a well-recognized side effect of angiotensin-converting enzyme (ACE) inhibitor therapy. Angioedema can also be seen with angiotensin receptor blocker therapy but much less frequently ...
- AACR: AstraZeneca next-gen PARP inhibitor gives 'bang for your buck' over firstcomers
The University of Texas MD Anderson Cancer Center’s Timothy Yap, M.D., doesn’t know why AstraZeneca’s PARP inhibitor saruparib seems to be spurring responses in patients who have previously ...
- Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain ...
- Bypassing interneurons: inhibition in neocortex
Whatever the answers may be, one thing is certain. Neocortical inhibition will never again seem simple.
- Next-gen Mpro inhibitor: Promising new drug candidate against Omicron and other SARS-CoV-2 variants
The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has so far claimed more than 6.8 million ...
Go deeper with Google Headlines on:
PAPD5 inhibition
[google_news title=”” keyword=”PAPD5 inhibition” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]